Apimeds Pharmaceuticals US (APUS)
Developing a bee-venom knee-osteoarthritis therapy and Bitcoin-treasury infrastructure.
Something off on this page? Send us feedback.
Develops Apitox, a purified bee-venom biologic for knee-osteoarthritis pain, while building MindWave's institutional Bitcoin-treasury and blockchain services. Both segments were pre-revenue in the latest disclosures, with clinical approval and third-party financial infrastructure central to commercialization.
Pairs a clinical-stage biologic with a digital-asset treasury and blockchain-platform business. The BioBusiness segment develops Apitox, a purified honeybee-venom injection proposed for knee-osteoarthritis pain and inflammation. The Digital Assets segment, through MindWave, is developing corporate Bitcoin treasury controls, yield programs, validator services and risk-monitoring tools.
Runs its executive office from Matawan, New Jersey; the digital-asset operation is headquartered in Singapore and includes an operation in the United Arab Emirates. U.S. Apitox rights and historical data come from Apimeds Korea, which retains proprietary analytical and manufacturing methods and receives a perpetual royalty.
Neither segment had generated revenue in the latest disclosures. Apitox needs a successful late-stage trial and FDA approval; planned digital services depend on regulated custodians and other infrastructure partners because direct custody, execution and intermediation are not licensed operations.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $278.4K · Total debt $14.6M · Total assets $127.6M · Shareholders' equity $106.4M
- Revenue
- $0
- Operating income
- −$6.3M
- Net income
- −$20.2M
No dividends on record.
| Institutions | 2.82% | 42.6K shares | |
|---|---|---|---|
| 7 holders · as of Jun 30, 2026 | |||
| Other | 97.18% | 1.47M shares | |
| remainder | |||
1.51M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Hemenway Trust Co LLCInstitution | 1.82% | 274,000 | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 0.42% | 63,654 | as of Jun 30, 2026 |
Geode Capital Management, LLCInstitution | 0.23% | 35,114 | as of Jun 30, 2026 |
Vanguard Fiduciary Trust CoInstitution | 0.16% | 24,039 | as of Jun 30, 2026 |
Jane Street Group, LLCInstitution | 0.11% | 15,993 | as of Jun 30, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- Coinbase
Institutional custody, trading and staking platform overlap.
- BitGo
Institutional custody and wallet infrastructure for treasury users.
- Pacira BioSciences
FDA-approved knee-OA injection for non-opioid pain treatment.
- Anika Therapeutics
Viscosupplement injections for the U.S. knee-OA pain market.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Apimeds Pharmaceuticals US | $1.74 | +4.19% | $2.5M | — | — | — | — |
| Coinbase | $199.35 | −0.85% | $53.04B | — | 305.0 | 9.6 | −18.5% |
| BitGo | $7.90 | +0.51% | $841.8M | — | 266.8 | 0.0 | — |
| Pacira BioSciences | $24.93 | +3.38% | $948.4M | 68.6 | 8.0 | 1.3 | +6.2% |
| Anika Therapeutics | $21.05 | +1.69% | $277.0M | — | 23.7 | 2.3 | +15.6% |
| Median | 68.6 | 145.2 | 1.8 | +6.2% |